TOP TEN perturbations for NM_000206 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000206
Selected probe(set): 204116_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000206 (204116_at) across 5392 perturbations tested by GENEVESTIGATOR:

PMA study 6 (500ng/ml) / vehicle (DME) treated bronchial epithelial cell sample

Relative Expression (log2-ratio):5.1569757
Number of Samples:3 / 17
Experimental PMA study 6 (500ng/ml)
Bronchial epithelial cells (NHBE) treated with tetradecanoylphorbol acetate (500ng/ml; vendor: Sigma / catalog number: P1585 / catalog name: Phorbol 12-myristate 13-acetate [16561-29-8]) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial). ATC code:---
Control vehicle (DME) treated bronchial epithelial cell sample
Bronchial epithelial cells (NHBE) treated with vehicle (DME) for 6 hours. For treatment primary cells were seeded at a density of 50'000 cells/well in pre-coated rat tail collagen type I 96-well plates for 24 hours followed by 4 hours starvation. NHBE cells were isolated from different Caucasian, healthy and non-smoker donors from the airway located above the bifurcation of the lungs (tracheal/bronchial).

glioma study 17 (anaplastic astrocytoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):4.5173216
Number of Samples:2 / 3
Experimental glioma study 17 (anaplastic astrocytoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade anaplastic astrocytoma (grade III). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 45 ? 18 years old.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.

mycosis fungoides study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):4.370987
Number of Samples:4 / 8
Experimental mycosis fungoides study 1 (tumor phase)
Lesional skin biopsies from patients with mycosis fungoides in the plaque phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast) / stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)

Relative Expression (log2-ratio):3.9639196
Number of Samples:3 / 4
Experimental stem cell differentiation study 50 (IRF2 shRNA; ASC; proerythroblast)
Proerythroblast differentiated from IRF2 (interferon regulatory factor 2) shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing shRNA targeting IRF2 gene with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.
Control stem cell differentiation study 50 (mock shRNA; ASC; proerythroblast)
Proerythroblast differentiated from control shRNA transduced hematopoietic stem/progenitor cells (CD34+). CD34+ hematopoietic stem/progenitor cells (HSC) were transduced with lentivirus expressing control shRNA with following differentiation to the erythroid lineage. HSCs were obtained from magnetically sorted G-CSF mobilized peripheral blood mononuclear cells of healthy donors. Cells were expanded in StemSpan SFEM medium supplied with Flt-3 ligand (100 ng/ml), SCF (100 ng/ml), IL-3 (20 ng/ml), IL-6 (20 ng/ml) and penicillin/streptomycin. Cells were harvested for total RNA extraction at the proerythroblast stage of differentiation.

lung adenocarcinoma study 9 (metastase; lymph node) / lung adenocarcinoma study 9 (metastase; brain)

Relative Expression (log2-ratio):3.7863646
Number of Samples:3 / 6
Experimental lung adenocarcinoma study 9 (metastase; lymph node)
Metastatic tumor tissue obtained from the lymph node of patients with primary lung adenocarcinoma.
Control lung adenocarcinoma study 9 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary lung adenocarcinoma.

mycosis fungoides study 1 (plaque phase) / normal skin tissue

Relative Expression (log2-ratio):3.5808764
Number of Samples:7 / 8
Experimental mycosis fungoides study 1 (plaque phase)
Lesional skin biopsies from patients with mycosis fungoides in the plaque phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

mycosis fungoides study 1 (patch phase) / normal skin tissue

Relative Expression (log2-ratio):3.4943676
Number of Samples:2 / 8
Experimental mycosis fungoides study 1 (patch phase)
Lesional skin biopsies from patients with mycosis fungoides in the patch phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):3.3537378
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

inclusion body myositis study 1 / normal biceps tissue

Relative Expression (log2-ratio):3.2586727
Number of Samples:5 / 3
Experimental inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).
Control normal biceps tissue
Biceps femoris biopsy muscle samples from control subjects.

necrotizing myopathy study 1 / inclusion body myositis study 1

Relative Expression (log2-ratio):-3.1602612
Number of Samples:3 / 5
Experimental necrotizing myopathy study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of necrotizing myopathy (NM).
Control inclusion body myositis study 1
Biceps femoris biopsy muscle samples from patients with clinical diagnosis of inclusion body myositis (IBM).